多奈哌齐联合阿米替林治疗神经衰弱伴发认知障碍患者的临床效果

Clinical Effect of Donepezil Combined with Amitriptyline in the Treatment of Patients with Neurasthenia and Cognitive Impairment

目的分析多奈哌齐联合阿米替林治疗神经衰弱伴发认知障碍患者的临床效果。方法选取2018年1月～12月我院收治的神经衰弱伴发认知障碍患者100例,随机分为对照组和研究组,各50例。对照组予以阿米替林治疗,研究组在对照组基础上加用多奈哌齐治疗,比较两组患者睡眠障碍、认知障碍、生活质量及不良反应发生情况。结果研究组睡眠障碍、认知障碍评分低于对照组[(3.57±1.02)分vs(7.25±1.64)分,(3.61±0.93)分vs(7.13±1.55)分],差异有统计学意义(P<0.05);研究组总发生率为6.00%,低于对照组的24.00%,差异有统计意义(P<0.05);研究组躯体功能、心理功能、物质生活、社会功能评分均高于对照组[(18.20±3.93)分vs (12.68±3.54)分,(18.59±3.62)分vs (13.77±3.32)分,(17.43±3.60)分vs (13.24±3.91)分,(17.89±3.62)分vs(12.53±3.78)分],差异有统计意义(P<0.05)。结论多奈哌齐联合阿米替林治疗神经衰弱伴发认知障碍患者,可改善患者睡眠障碍、认知障碍,有效提高生活质量,减少患者不良反应的发生。

Objective To analyze the clinical effects of donepezil combined with amitriptyline in the treatment of patients with neurasthenia and cognitive impairment. Methods 100 patients with neurasthenia and cognitive impairment admitted to our hospital from January to December 2018 were randomly divided into control group and study group, 50 cases each. The control group was treated with amitriptyline. The study group was treated with donepezil on the basis of the control group. The sleep disorder, cognitive impairment, quality of life and adverse reactions were compared between the two groups. Results The scores of sleep disorder and cognitive impairment in the study group were lower than those in the control group [(3.57±1.02) points vs (7.25±1.64)points,(3.61±0.93) points vs (7.13±1.55) points], and the difference was statistically significant (P<0.05);the total incidence rate of the study group was 6.00%, which was lower than that of the control group 24.00%,the difference was statistically significant (P<0.05). The physical function, psychological function, material life and social function scores of the study group were higher than the control group[(18.20±3.93) points vs (12.68±3.54) points,(18.59±3.62) points vs (13.77±3.32) points,(17.43±3.60) points vs (13.24±3.91) points,(17.89±3.62) points vs (12.53 ± 3.78) points, the difference was statistically significant (P<0.05). Conclusion Donepezil combined with amitriptyline in the treatment of patients with neurasthenia and cognitive impairment can improve sleep disorders and cognitive impairment, improve quality of life and reduce adverse reactions.